Tagged with access,

France Emmanuelle Quilès, CEO of Janssen France, speaks about how she joined the American multinational with the ambition to bring digitalization and transform the organization from the inside. Quilès goes on to cover the operational specifics of the affiliate and shares her insights on the French pharma ecosystem.   When I…

France Franck Hamalian, general manager of the French affiliate of Aspen, a specialty and branded multinational pharmaceutical company from South Africa, discusses the Group’s unique business model which revolves around strategic acquisitions and strong productive capabilities. Additionally, he describes the French ecosystem regarding key topics such as big data and market…

France Newly-appointed general manager of UCB France, Catherine Rives, discusses what drew her back to the company after time away, market access issues in France and the future of personalized medicine.   My mission is very clearly to raise the profile of the French affiliate within the UCB Group and simultaneously…

France Guillaume El Glaoui, co-founder and CEO of Laboratoires Majorelle, discusses what spurred the creation of the company, its success of gaining the first reimbursement ever of a condom in France, and the company’s core philosophy of social responsibility to public health.   We started with contraception and after a few…

USA 59 novel drugs were approved in the USA in 2018, representing a leap from the 46 approved in 2017 and 22 approved in 2016. 19 of the 59 drugs (32 percent) have been designated ‘first-in-class’ and 34 of the 59 drugs (58 percent) were approved to treat rare or “orphan”…

Canada In total there were 27 new active substances (NASs) approved in Canada in 2018, 18 prescription pharmaceutical drugs and 9 biologics. In terms of companies that saw particular success last year, Merck (MSD outside of the US and Canada) had three prescription drugs approved, as did Swiss-headquartered Vifor Pharma. Global…

Spain Sergio Rodriguez, CEO of Pfizer Spain, highlights the strength of the affiliate and the importance for the company in Europe, as well as the key areas that are driving their growth. Furthermore, he gives an overview of the need for innovative companies to partner with key stakeholders and illustrates what…

Spain Marieta Jiménez, president and general manager of Merck Spain, highlights her three top priorities: innovation, science and technology, and women’s equality. Furthermore, she gives an overview of the need for better collaboration for long-term sustainably of the Spanish healthcare system and breaks down the role of the ClosingGap cluster to…

Spain Ramón Villamarín Valdenebro, general manager of Shionogi Spain, highlights the key steps that needed to be taken to establish the affiliate over the last 18 months and his plans to grow its portfolio, both in the pharmacy and hospital sector. Furthermore, he gives an overview of how the company has…

Korea Julien Samson, vice president and general manager of GSK Korea explains how GSK’s new global strategy is being delivered within the Korean affiliate. Mr Samson explains the focus areas for GSK – vaccines, HIV and respiratory treatments, and provides an insight into how GSK can best utilize Korea’s strong environment…

Korea Uloff Münster, general manager of Merck Biopharma Korea provides his insights into the Korean healthcare system. Dr Münster also discusses the drug pricing situation in Korea and the potential for companies like Merck to utilize local partnerships.   We are in the process of preparing launches of our new molecules…

Spain Fernando Álvarez, director general of Allergan Iberia, highlights the market’s shift towards more holistic innovation and the company’s main growth drivers, especially in the field of aesthetics. Furthermore, he touches on the importance of the market access team in the fragmented Spanish healthcare ecosystem and his ambitions for Allergan throughout…